936844-08-5

Upstream product

• 112-35-6 triethylene glucol monomethyl ether 
• 18242-39-2 3,5-dinitrobromobenzene 
• 72593-77-2 3,6,9-trioxadecyl bromide 
• 116632-23-6 3-bromo-5-nitro-phenol 

Downstream Products

• 1610449-80-3 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((3-ethynyl-5-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)urea 
• 1610450-55-9 1-ethynyl-3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-nitrobenzene 
• 1610450-56-0 3-ethynyl-5-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)aniline 
• 1610450-54-8 triisopropyl((3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-nitrophenyl)ethynyl)silane 
• 936844-11-0 2,2,2-trifluoro-N-{3-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}-5-[(trimethylsilyl)-ethynyl]phenyl}acetamide 
• 936844-12-1 N-(3-ethynyl-5-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}phenyl)-2,2,2-trifluoroacetamide 
• 936844-10-9 N-(3-bromo-5-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}phenyl)-2,2,2-trifluoroacetamide 
• 936844-09-6 3-bromo-5-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}aniline 

Relevant academic research and scientific papers

KINASE INHIBITORS

There are provided compounds of formula I, (I) wherein R1 to R5, Ar and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

KINASE INHIBITORS

There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

UREA DERIVATIVES USEFUL AS KINASE INHIBITORS

There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Covalent assembly of molecular ladders

[n]-Rung molecular ladders (n = 3-6) have been prepared by reacting discrete, complimentary m-phenylene ethynylene oligomers using imine formation/exchange. The nanostructures, which in the largest case measure approximately 1.6 × 6.2 nm, have been charac